We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

As the U.S. market experiences a modest rebound with key indices like the S&P 500 and Nasdaq Composite extending their winning streaks, investors are closely monitoring developments in trade talks and ...

Goldman Sachs analysts led by Steven Kron share the firm's latest conviction list, which includes 23 of the bank's top picks ...

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

Shares of Charles River Laboratories International Inc. rallied 3.42% to $143.22 Wednesday, on what proved to be an ...

In a precedential decision issued June 4, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed a district court's finding of noninfringement in favor of Moderna, Inc. in its ongoing ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

Detailed price information for Rocket Pharmaceuticals Inc (RCKT-Q) from The Globe and Mail including charting and trades.